Review Advances in imaging—Elastography Dajti et al. #LiverX tinyurl.com/stxxfad9

Hepatitis B virus infection remains a major public health threat, affecting an estimated 254 million people worldwide. What's the latest evidence on its epidemiology, virology, immunology, and clinical management? A State of the Art Review ⬇️ #MedEd bmj.com/content/389/bm…

Original Article Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection Hui et al. #LiverX tinyurl.com/25xyd7ev

Excited to share our new manuscript on a risk-stratified approach to PBC, now published in The Lancet Gastroenterology & Hepatology Many thanks to Dr. Hirschfield for the incredible mentorship throughout this project! Treat wisely! Treat to targets! #livertwitter thelancet.com/journals/langa…

New research - Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial thelancet.com/journals/langa… #LiverTwitter #MedTwitter

Original Article: Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY trial) nej.md/4kru98f Editorial: Redefining End Points in MASH Cirrhosis nej.md/4lldvHs #Gastroenterology

Just interviewed a truly remarkable family — their youngest son Caleb is a liver transplant recipient. His father Brian was the donor, and his mother brittany munn now advocates with a powerful pediatric liver transplant group Society of Pediatric Liver Transplantation (SPLIT) . With AnnMarie Liapakis & Nadia Ovchinsky, MD, MBA, FAASLD. @SiriusXM

Review Article Mendelian randomization in hepatology: A review of principles, opportunities, and challenges. Song et al. #LiverX tinyurl.com/ddh3b7rn

CIRROXABAN Study is finally here! 🔬 First DB RCT evaluating rivaroxaban in cirrhosis 💡 Complication-free survival benefit in Child‑Pugh B7 (HR 0.26 [95 % CI 0.07–0.90]). ⚠️ Mild bleeding ↑, but no increase in severe events. 📄 journal-of-hepatology.eu/article/S0168-…

What to use Peth to differentiate SLD sub-type- here's how to do it based upon latest evidence- our collaborative piece with Hannes and Luis MASLD Research Center UCSD Gastroenterology Emerging Role of Phosphatidylethanol Testing in Clinical Practice for ... sciencedirect.com/science/articl… Elliot Tapper

New Review - Recompensation in decompensated cirrhosis thelancet.com/journals/langa… #LiverTwitter #MedTwitter

New Comment - Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials thelancet.com/journals/langa… Lewis Roberts #LiverTwitter #OncTwitter #MedTwitter

🌟Hot off the press! Our newest special issue dives into the promise and perils of #AI in #gastroenterology and #hepatology. 📖Browse the issue here: ow.ly/fbZa50WCTgL #ArtificialIntelligence #genAI #GI

MASLD has become the most common chronic liver disease worldwide. Giovanni Targher, MD, Luca Valenti, MD (Luca Valenti), and Christopher D. Byrne, MB, ChB, review the features of the disease as well as pharmacotherapies targeting the associated liver and

New research - Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis thelancet.com/journals/langa… #LiverTwitter #IDTwitter #MedTwitter

💥A simple & reliable #POCUS method to assess #sarcopenia in #cirrhosis - now in JHEP Reports ✅ Accurate vs CT ⚡️ Fast (1-min test) 💵 Low-cost 🎯 Linked to clinical outcomes 🏥 sciencedirect.com/science/articl… HEPOCUS (Liver POCUS) M PREMKUMAR Annalisa Berzigotti Cirrhosis Care Alberta Elliot Tapper EASLnews

🆕ACG Guideline: ➡ Perioperative Risk Assessment & Management in Cirrhosis How to: 1️⃣Assess & Optimize for surgery cirrhosis patients with low risk 2️⃣Avoid surgery in those with high risk journals.lww.com/ajg/fulltext/2…

In patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence, perioperative camrelizumab plus rivoceranib significantly improved event-free survival compared with surgery alone, suggests new study. hubs.li/Q03Pf8xC0 #ESMO25

#Hepatitis B #HBV 2⃣ important lessons: ⏩Even Low #HBVDNA level viremia promotes🕸️#liver fibrosis ⏩Viral suppression in #decompensated #cirrhosis improves outcomes but MELD >20 may indicate a point of no return #WHO still much to do in #HBV EASLnews APASL News AASLD

🟣Cystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor 🔓#OpenAccess at👉jhep-reports.eu/article/S2589-… #LiverTwitter #LiverX #CysticFibrosis